Phase 1 SPONTAN® study accepted for podium presentation at 2026 World Meeting on Sexual Medicine

Results from LTR Pharma’s independent Phase I clinical study of SPONTAN® nasal spray have been accepted for podium presentation at one of the leading global congresses in sexual medicine - the 2026 World Meeting on Sexual Medicine (WMSM), to be held in Portugal next month. 

The accepted abstract, entitled “Evaluation of Pharmacokinetics Profile and Safety Outcomes Comparing Nasal SPONTAN versus Oral Vardenafil Formulations”, will be presented by Professor Eric Chung and reports results from a Phase I, open-label, randomised, single-dose crossover study conducted in healthy adult males. 

The findings of the study demonstrated that SPONTAN achieved faster absorption than the oral vardenafil tablets, with a notably shorter time to peak concentration. When adjusted for dose, SPONTAN also showed higher bioavailability despite being administered at a lower dose.  

LTR Pharma Scientific Advisory Board member, Professor Eric Chung, said: 

“The acceptance of this study for podium presentation at WMSM reflects strong international scientific interest in the SPONTAN nasal spray program. The pharmacokinetic profile observed highlights the potential advantages of intranasal delivery compared to oral tablets, particularly in terms of speed of absorption, which is highly relevant in the clinical management of erectile dysfunction.” 

Click to read the ASX release.